On January 17, 2024, UroGen Pharma Ltd. announced its plan to initiate a Phase 3 study in 2024 to explore the safety and efficacy of UGN-103 in low-grade, intermediate risk, non-muscle invasive bladder cancer. UGN-103 is intended to be a next-generation version of UGN-102 that combines medac?s mitomycin formulation (i.e., the Product) with the Company?s RTGel technology, which the Company believes will provide advantages related to production, cost, supply and product convenience. With medac?s intellectual property protection for its mitomycin formulation expected to last until June 2035 and the Company?s pending U.S. patent applications, the Company projects potential intellectual property protection on UGN-103 until December 2041.